Streptozocin is a drug approved by U.S. Food and Drug Administration (USFDA) for the treatment of pancreatic islet cells cancer. Streptozocin is classified as an alkylating agent, which produces anti-cancer effects by causing a chemical reaction that damages the DNA in a cell. The DNA damage caused by streptozocin results in the cell death. Streptozocin damages pancreatic cells causing hyperglycemia, so, also used in medical research to produce an animal model for hyperglycemia.

Streptozocin Market– Driver

Increasing research activities using streptozocin is expected to propel growth of the streptozocin market during the forecast period. For instance, an article published in the journal Nature in February 2018, stated that streptozocin may reduce the virulence of Staphylococcus aureus. It is a Gram-positive human pathogen, which colonizes at skin and other mucosal surface and causes various diseases ranging from skin and soft-tissue infections, endocarditis, toxic shock syndrome, and necrotizing pneumonia. The virulence gene in the bacteria can be targeted by streptozocin.

Streptozocin Market– Restraint

Shortages of streptozocin in the global market during the forecast period my affect the growth of streptozocin in global market. For instance, according to Drug Shortages of Canada in March 2017, Zanosar sterile powder for solution manufactured by PALADIN LABS INC., containing streptozocin was on shortage in 2017. The drug was manufactured by Furthermore, rising prevalence of kidney diseases are negatively inhibiting the growth of streptozocin in global market since streptozocin is contraindicated in the kidney diseases due to renal toxicity. For instance, according to national Institute of Diabetes and Digestive and Kidney Diseases, of U.S., in 2015, overall prevalence of Chronic Kidney Disease (CKD) in the general population in U.S. was around 14 percent in 2015, which my hamper growth of the streptozocin market.

Streptozocin Market– Regional Analysis

On the basis of region, the global streptozocin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America region is estimated to hold highest position in global streptozocin market during the forecast period due to rising prevalence of pancreatic cancer among population of U.S. For instance, according to National Cancer Institute 2015 statistics, an estimated 68,615 people were living with pancreatic cancer in the U.S. and about 55,440 new cases are estimated to be diagnosed with pancreatic cancer during 2018.

Asia Pacific is projected to witness significant growth in the global streptozocin market during the forecast period, owing to increasing awareness regarding pancreatic cancer and its management. For instance, in November 2017, PanCAN organized Purple Stride charity run and walk event, which aimed to increase awareness regarding pancreatic cancer. PanCAN is a nonprofit network in Japan for people fighting with pancreatic cancer. Japan Pancreatic Cancer Action Network (PanCAN Japan) organizes November as a Pancreatic Cancer Awareness Month.

Key players operating in streptozocin market include Sigma-Aldrich, Inc., LGM Pharma., Xiamen Hisunny Chemical Co Ltd, Beijing Yunbang Biosiciences Co Ltd, Neostar United Industrial Co Ltd, Haihang Industry Co Ltd, Shaanxi Top Pharm Chemical Co Ltd, and Chengdu Yuyang High-Tech Developing Co Ltd.

Streptozocin Market– Taxonomy

By Product Type